Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Drug-induced hepatitis following use of octreotide for long-term treatment of congenital hyperinsulinism.

Avatapalle B, Padidela R, Randell T, Banerjee I.

BMJ Case Rep. 2012 Jul 30;2012. pii: bcr2012006271. doi: 10.1136/bcr-2012-006271.

2.

Octreotide-induced hepatitis in a child with persistent hyperinsulinemia hypoglycemia of infancy.

Ben-Ari J, Greenberg M, Nemet D, Edelstein E, Eliakim A.

J Pediatr Endocrinol Metab. 2013;26(1-2):179-82. doi: 10.1515/jpem-2012-0349.

PMID:
23327813
3.

Hepatitis in an infant treated with octreotide for congenital hyperinsulinism.

Koren I, Riskin A, Barthlen W, Gillis D.

J Pediatr Endocrinol Metab. 2013;26(1-2):183-5. doi: 10.1515/jpem-2012-0372.

PMID:
23327817
4.

Long-term follow-up of children with congenital hyperinsulinism on octreotide therapy.

Demirbilek H, Shah P, Arya VB, Hinchey L, Flanagan SE, Ellard S, Hussain K.

J Clin Endocrinol Metab. 2014 Oct;99(10):3660-7. doi: 10.1210/jc.2014-1866. Epub 2014 Jun 17.

PMID:
24937539
5.

Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon.

Mohnike K, Blankenstein O, Pfuetzner A, Pötzsch S, Schober E, Steiner S, Hardy OT, Grimberg A, van Waarde WM.

Horm Res. 2008;70(1):59-64. doi: 10.1159/000129680. Epub 2008 May 21.

PMID:
18493152
6.

Octreotide-associated cholestasis and hepatitis in an infant with congenital hyperinsulinism.

Levy-Khademi F, Irina S, Avnon-Ziv C, Levmore-Tamir M, Leder O.

J Pediatr Endocrinol Metab. 2015 Mar;28(3-4):449-51. doi: 10.1515/jpem-2014-0119.

PMID:
25324442
7.

Octreotide-induced long QT syndrome in a child with congenital hyperinsulinemia and a novel missense mutation (p.Met115Val) in the ABCC8 gene.

Celik N, Cinaz P, Emeksiz HC, Hussain K, Çamurdan O, Bideci A, Döğer E, Yüce Ö, Türkyılmaz Z, Oğuz AD.

Horm Res Paediatr. 2013;80(4):299-303. doi: 10.1159/000354666. Epub 2013 Sep 27.

PMID:
24080777
8.

Nifedipine in Congenital Hyperinsulinism - A Case Report.

Khawash P, Hussain K, Flanagan SE, Chatterjee S, Basak D.

J Clin Res Pediatr Endocrinol. 2015 Jun;7(2):151-4. doi: 10.4274/jcrpe.1978.

9.

Efficacy and safety of long-term, continuous subcutaneous octreotide infusion for patients with different subtypes of KATP-channel hyperinsulinism.

Yorifuji T, Kawakita R, Hosokawa Y, Fujimaru R, Matsubara K, Aizu K, Suzuki S, Nagasaka H, Nishibori H, Masue M.

Clin Endocrinol (Oxf). 2013 Jun;78(6):891-7. doi: 10.1111/cen.12075. Epub 2013 Apr 6.

PMID:
23067144
10.

Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism.

Laje P, Halaby L, Adzick NS, Stanley CA.

Pediatr Diabetes. 2010 Mar;11(2):142-7. doi: 10.1111/j.1399-5448.2009.00547.x. Epub 2009 Jun 25. Review.

PMID:
19558634
11.

Seizure due to somatostatin analog discontinuation in a case diagnosed as congenital hyperinsulinism novel mutation.

Baş VN, Ozkan M, Zenciroğlu A, Cavuşoğlu YH, Cetinkaya S, Aycan Z.

J Pediatr Endocrinol Metab. 2012;25(5-6):553-5.

PMID:
22876555
12.

An Egyptian case of congenital hyperinsulinism of infancy due to a novel mutation in KCNJ11 encoding Kir6.2 and response to octreotide.

Sherif EM, Abdelmaksoud AA, Elbarbary NS, Njølstad PR.

Acta Diabetol. 2013 Oct;50(5):801-5. doi: 10.1007/s00592-010-0217-1. Epub 2010 Aug 5.

PMID:
20686794
13.

Successful treatment of congenital hyperinsulinism with long-acting release octreotide.

Le Quan Sang KH, Arnoux JB, Mamoune A, Saint-Martin C, Bellanné-Chantelot C, Valayannopoulos V, Brassier A, Kayirangwa H, Barbier V, Broissand C, Fabreguettes JR, Charron B, Thalabard JC, de Lonlay P.

Eur J Endocrinol. 2012 Feb;166(2):333-9. doi: 10.1530/EJE-11-0874. Epub 2011 Nov 2.

14.

A combination of nifedipine and octreotide treatment in an hyperinsulinemic hypoglycemic infant.

Durmaz E, Flanagan SE, Parlak M, Ellard S, Akcurin S, Bircan I.

J Clin Res Pediatr Endocrinol. 2014;6(2):119-21. doi: 10.4274/Jcrpe.1230.

15.

Use of Long-Acting Somatostatin Analogue (Lanreotide) in an Adolescent with Diazoxide-Responsive Congenital Hyperinsulinism and Its Psychological Impact.

Shah P, Rahman SA, McElroy S, Gilbert C, Morgan K, Hinchey L, Senniappan S, Levy H, Amin R, Hussain K.

Horm Res Paediatr. 2015;84(5):355-60. doi: 10.1159/000439131. Epub 2015 Sep 17.

PMID:
26375451
16.

Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism.

Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA.

J Pediatr. 1993 Oct;123(4):637-43.

PMID:
8410522
17.

Cognitive and developmental outcome of conservatively treated children with congenital hyperinsulinism.

Levy-Shraga Y, Pinhas-Hamiel O, Kraus-Houminer E, Landau H, Mazor-Aronovitch K, Modan-Moses D, Gillis D, Koren I, Dollberg D, Gabis LV.

J Pediatr Endocrinol Metab. 2013;26(3-4):301-8. doi: 10.1515/jpem-2012-0289.

PMID:
23327786
18.

Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers.

Welters A, Lerch C, Kummer S, Marquard J, Salgin B, Mayatepek E, Meissner T.

Orphanet J Rare Dis. 2015 Nov 25;10:150. doi: 10.1186/s13023-015-0367-x. Review.

19.

Octreotide in hyperinsulinism.

Barrons RW.

Ann Pharmacother. 1997 Feb;31(2):239-41. Review.

PMID:
9034427
20.

Novel mutation c.597_598dup in exon 5 of ABCC8 gene causing congenital hyperinsulinism.

Jindal R, Ahmad A, Siddiqui MA, Kochar IS, Wangnoo SK.

Diabetes Metab Syndr. 2014 Jan-Mar;8(1):45-7. doi: 10.1016/j.dsx.2013.02.018. Epub 2013 Mar 26.

PMID:
24661758
Items per page

Supplemental Content

Write to the Help Desk